Biogen Idec Gets Potential Oral Tysabri Follow-on In UCB Deal
This article was originally published in The Pink Sheet Daily
The company's second oral multiple sclerosis candidate employs the same mechanism as Tysabri and is set to enter Phase II early next year.
You may also be interested in...
In Phase II studies, 77% of patients treated with Novartis' FTY720 remained relapse free after two years.
Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.
Biogen Idec expects to re-launch the multiple sclerosis therapy in July.